pharmaphorum Podcast

Europe for life sciences and for patients, with BeOne Medicines

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Europe continues to offer major life sciences advantages: deep scientific t

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* When it comes to digital innovation and AI, consideration of using and impl

Delivering prevention at scale, PA Consulting’s James Davis

Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at

Understanding Operation Trialblazer, with Dr Harpreet Singh

For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lig

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients a

Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the age

CAMP4 on a new class of ASO in gene under expression

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and

BonelliErede on M&A in Europe: Andrea Carta Mantiglia

The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe

Purespring on nephrology & gene therapy in kidney disease

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. In a new pharmaphor

Parexel: Flawless execution, policy shifts & patient-centric design

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. In a new pharmaphorum podcast,

Citius’ Leonard Mazur talks targeted immune therapy for CTCL

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immun

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increas

Biosimilars & patient access independent of geographies or socioeconomics, with Rebecca Guntern

2026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and othe

Towards a healthier world: Momentum in UK health system transformation, with Lee-Ann Farrell

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like

Trustworthy and novel AI in clinical trial planning, with Kris Kaneta

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up de

The cardio-renal-metabolic space and obesity as a chronic disease, with Ramy Younes

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism,

On the power of T-cells, with Cedrik Britten

In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immuno

Why everyone should care about longevity, with Boyang Wang

Longevity and healthspan have emerged rapidly as an increasingly serious category of healthcare study and investment. But there are a lot of ideas inside the industry and

A philosophical look at market turn in the Age of AI, with John Holodnak

Today, the life sciences sector is prioritising recruitment of leaders who can scale efficiently in capital-constrained environments, as well as focusing on hybrid operat

Providing patient access to new therapies, with Dean Erhardt

Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of usi